Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.

ABSTRACT:

Purpose

High-throughput sequencing (HTS) of immunoglobulin heavy-chain genes (IGH) in unselected clinical samples for minimal residual disease (MRD) in B lymphoblastic leukemia (B-ALL) has not been tested. As current MRD-detecting methods such as flow cytometry or patient-specific qPCR are complex or difficult to standardize in the clinical laboratory, sequencing may enhance clinical prognostication.

Experimental design

We sequenced IGH in paired pretreatment and day 29 post-treatment samples using residual material from consecutive, unselected samples from the Children's Oncology Group AALL0932 trial to measure MRD as compared with flow cytometry. We assessed the impact of ongoing recombination at IGH on MRD detection in post-treatment samples. Finally, we evaluated a subse

SUBMITTER: Wu D 

PROVIDER: S-EPMC5142743 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature